AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A composition comprising:

(a) an antibody or an epitope-binding fragment thereof, wherein said antibody or said fragment specifically binds to insulin-like growth factor-I receptor, and wherein said antibody has the same binding specificity as murine antibody EM164, and wherein said antibody or said fragment is substantially devoid of agonist activity; and

(b) a therapeutic agent.

2. (previously presented) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor antibody, thalidomide, carmustine, prednisone, interferon alpha-2a, vincristine, pamidronate, erythropoietin, bisphosphonate and an epothilone.

3. (previously presented) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, and camptothecin.

4.-5. (canceled).

6. (previously presented) A pharmaceutical composition comprising the composition of claim 1, and a pharmaceutically acceptable carrier or diluent.

7. (previously presented) The composition of claim 1, wherein said antibody or said fragment comprises

a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region comprises three sequential complementarity-determining regions comprising the amino acid sequences of SEQ ID NOs:1-3, respectively.

8. (currently amended): The composition of claim 1, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three sequential complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:1-3~~, respectively~~;

and wherein said light chain variable region comprises three sequential complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:4-6, ~~respectively:~~respectively.

9. (previously presented) The composition of claim 1, wherein said antibody or said fragment comprises a heavy chain variable region that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:7.

10. (previously presented) The composition of claim 9, wherein said heavy chain variable region has at least 95% sequence identity to said amino acid sequence of SEQ ID NO:7.

11. (previously presented) The composition of claim 9, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:7.

12. (previously presented) The composition of claim 1,

wherein said antibody or said fragment comprises a light chain variable region that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:8.

13. (previously presented) The composition of claim 12, wherein said light chain variable region has at least 95% sequence identity to said amino acid sequence of SEQ ID NO:8.

14. (previously presented) The composition of claim 12, wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:8.

15. (previously presented) The composition of claim 1, wherein said antibody or said fragment comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of:

SEQ ID NO:9;

SEQ ID NO:10;

SEQ ID NO:11; and

SEQ ID NO:12.

16. (currently amended) The composition of claim 1, wherein said antibody or said fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13~~NO:13~~).

17. (previously presented) The composition of any one of claims 7-16, wherein said therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor antibody, thalidomide, carmustine, prednisone, interferon alpha-2a, vincristine, pamidronate, erythropoietin, bisphosphonate and an epothilone.

18. (previously presented) The composition of any one of claims 7-16, wherein said therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, and camptothecin.

19. (original) A method for inhibiting the growth of a cancer cell comprising contacting said cell with the composition of claim 1.

20. (withdrawn) A method for treating a patient having a cancer comprising administering to said patient an effective amount of the composition of claim 1.

21. (withdrawn) A method for treating a patient having a cancer comprising administering to said patient an effective amount of the pharmaceutical composition of claim 6.

22. (previously presented) The method of any one of claims 19-21, wherein said cancer is a cancer selected from the group consisting of breast cancer, colon cancer, ovarian carcinoma, osteosarcoma, cervical cancer, prostate cancer, lung cancer, synovial carcinoma, pancreatic cancer, melanoma, multiple myeloma, neuroblastoma, and rhabdomyosarcoma.

23. (cancelled).

24. (previously presented) A method for inhibiting the growth of a cancer cell comprising contacting a cancer cell with the composition of claim 1.

25. (withdrawn - previously presented) A method for treating a patient having a cancer comprising administering to said patient having a cancer an effective amount of the composition of claim 1.

26. (previously presented) The method of claim 24, wherein said cell is contacted with said antibody or said fragment and said therapeutic agent concurrently.

27. (previously presented) The method of claim 24, wherein said cell is contacted with said antibody or said fragment and said therapeutic agent sequentially and in either order.

28. (withdrawn - previously presented) The method of claim 25, wherein said antibody or said fragment and said second therapeutic agent are administered concurrently.

29. (withdrawn - previously presented) The method of claim 25, wherein said antibody or said fragment and said second therapeutic agent are administered sequentially and in either order.

30. (previously presented): The method of claim 24 or 25, wherein said therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin,

rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor antibody, thalidomide, carmustine, prednisone, interferon alpha-2a, vincristine, pamidronate, erythropoietin, bisphosphonate and an epothilone.

31. (previously presented) The method of claim 24 or 25, wherein said therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, and camptothecin.

32. (previously presented) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, thalidomide, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, carmustine, prednisone, zoledronate, erythropoietin, bisphosphonate and dexamethasone.

33. (previously presented) The composition of any one of claims 7-16, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, thalidomide, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, carmustine, prednisone, zoledronate, erythropoietin, bisphosphonate and dexamethasone.

34. (previously presented) The method of claim 24 or 25, wherein said therapeutic agent is selected from the group consisting of bortezomib, melphalan, thalidomide, doxorubicin,

cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, carmustine, prednisone, zoledronate, erythropoietin, bisphosphonate and dexamethasone.

35. (withdrawn) The method according to claim 20, wherein said effective amount of the composition of claim 1 comprises about 1 mg/square meter to about 2000 mg/square meter of said antibody or fragment thereof, and about 10 mg/square meter to about 2000 mg/square meter of said therapeutic agent.

36. (withdrawn) The method according to claim 20, wherein said effective amount of the composition of claim 1 comprises about 10 mg/square meter to about 1000 mg/square meter of said antibody or fragment thereof, and about 50 mg/square meter to about 1000 mg/square meter of said therapeutic agent.

37. (previously presented) The composition of claim 1, wherein said antibody or said fragment is selected from the group consisting of:

(i) a resurfaced antibody or epitope binding fragment thereof;

(ii) a human antibody or epitope binding fragment thereof;

(iii) a humanized antibody or epitope binding fragment thereof; and

(iv) an antibody produced by mouse hybridoma EM164 (ATCC accession number PTA 4457) or epitope binding fragment thereof.